Q2 2023 Ascelia Pharma AB Earnings Call Transcript
Thank you. And welcome, everyone, to the webcast for Ascelia Pharma's Q2 report 2023. I am Magnus Corfitzen, CEO of Ascelia Pharma.
And with me today, I have Julie Brogren, Deputy CEO and Chief Commercial Officer; Déspina Georgiadou, Chief Financial Officer; and Andreas Norlin, Chief Scientific Officer. We will go through the quarterly presentation and then open up for questions from the audience.
We will be making forward-looking statements on this call, so please pay attention to this.
Ascelia Pharma is dedicated to improve the life of people living with cancer by offering better treatment options. In particular, we focus on rare cancer conditions. Our business model is to identify, develop, and commercialize novel drugs that address unmet medical needs within orphan oncology.
We have two drugs in clinical development. Orviglance has completed patient enrollment in a global Phase 3 clinical study. Orviglance also has orphan drug designation from the FDA and is targeting an addressable market opportunity of $800 million.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |